Chimerix, Inc.

Chimerix reported financial results for Q4 and full-year 2024, with a net loss of $23 million and $88.4 million, respectively. The company's NDA for dordaviprone, a treatment for recurrent H3 K27M-mutant diffuse glioma, is under review by the FDA with a PDUFA action date of August 18, 2025. Chimerix is also expected to be acquired by Jazz Pharmaceuticals in Q2 2025.

Related tickers: CMRX, JAZZ.

Halper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales of Redfin, Blackboxstocks, Chimerix, and Walgreens Boots Alliance.

Related tickers: RDFN, BLBX, CMRX, WBA.